Literature DB >> 16442208

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Richard J Sylvester1, Adrian P M van der Meijden, Willem Oosterlinck, J Alfred Witjes, Christian Bouffioux, Louis Denis, Donald W W Newling, Karlheinz Kurth.   

Abstract

OBJECTIVES: To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection.
METHODS: A combined analysis was carried out of individual patient data from 2596 superficial bladder cancer patients included in seven European Organization for Research and Treatment of Cancer trials.
RESULTS: A simple scoring system was derived based on six clinical and pathological factors: number of tumors, tumor size, prior recurrence rate, T category, carcinoma in situ, and grade. The probabilities of recurrence and progression at one year ranged from 15% to 61% and from less than 1% to 17%, respectively. At five years, the probabilities of recurrence and progression ranged from 31% to 78% and from less than 1% to 45%.
CONCLUSIONS: With these probabilities, the urologist can discuss the different options with the patient to determine the most appropriate treatment and frequency of follow-up.

Entities:  

Mesh:

Year:  2006        PMID: 16442208     DOI: 10.1016/j.eururo.2005.12.031

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  682 in total

1.  Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer.

Authors:  Willemien Beukers; Raju Kandimalla; Roy G Masius; Marcel Vermeij; Ries Kranse; Geert Jlh van Leenders; Ellen C Zwarthoff
Journal:  Mod Pathol       Date:  2014-11-14       Impact factor: 7.842

Review 2.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Additive antitumoral effect of interleukin-12 gene therapy and chemotherapy in the treatment of urothelial bladder cancer in vitro and in vivo.

Authors:  Wanpeng Liu; Yanwei Cao; Mario I Fernández; Haitao Niu; Youcheng Xiu
Journal:  Int Urol Nephrol       Date:  2010-11-12       Impact factor: 2.370

4.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

5.  Wide-field autofluorescence-guided TUR-B for the detection of bladder cancer: a pilot study.

Authors:  Maximilian C Kriegmair; P Honeck; M Theuring; C Bolenz; M Ritter
Journal:  World J Urol       Date:  2017-12-06       Impact factor: 4.226

6.  Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.

Authors:  J Palou; F Pisano; R Sylvester; S Joniau; V Serretta; S Larré; S Di Stasi; B van Rhijn; A J Witjes; A Grotenhuis; R Colombo; A Briganti; M Babjuk; V Soukup; P U Malmstrom; J Irani; N Malats; J Baniel; R Mano; T Cai; E K Cha; P Ardelt; J Varkarakis; R Bartoletti; G Dalbagni; S F Shariat; E Xylinas; R J Karnes; P Gontero
Journal:  World J Urol       Date:  2018-05-02       Impact factor: 4.226

7.  Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer.

Authors:  Faysal A Yafi; Armen G Aprikian; Joseph L Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; Fred Saad; David Bell; Darrel Drachenberg; Wassim Kassouf
Journal:  World J Urol       Date:  2013-11-10       Impact factor: 4.226

8.  Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia.

Authors:  Tom J H Arends; Johannes Falke; Rianne J M Lammers; Diederik M Somford; Jan C M Hendriks; Mirjam C A de Weijert; Harm C Arentsen; Antoine G van der Heijden; Egbert Oosterwijk; J Alfred Witjes
Journal:  World J Urol       Date:  2014-12-10       Impact factor: 4.226

9.  Long non-coding RNA HNF1A-AS1 promotes cell viability and migration in human bladder cancer.

Authors:  Zhihong Feng; Baolong Wang
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

10.  The efficacy and safety of simultaneous transurethral GreenLight photoselective vaporization of bladder tumor and prostate in patients with bladder tumor and lower urinary tract symptoms.

Authors:  Zhaoyi Li; Ruipeng Hou; Jian Li
Journal:  Int Urol Nephrol       Date:  2013-10-05       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.